EPO Patent Bulletin: Antigen-binding proteins targeting CD56
Summary
The European Patent Office has published patent application EP3328994A1 concerning antigen-binding proteins targeting CD56 and their uses. The patent was filed by Memorial Sloan-Kettering Cancer Center and the U.S. Department of Health and Human Services.
What changed
This document is a publication of a European patent application (EP3328994A1) related to antigen-binding proteins targeting CD56. The patent application was filed by Memorial Sloan-Kettering Cancer Center and the U.S. Department of Health and Human Services, with a publication date of March 11, 2026.
This is a patent publication and does not impose direct compliance obligations on regulated entities. However, it is relevant for companies operating in the pharmaceutical and biotechnology sectors, particularly those involved in the development of cancer therapies or immunology, as it pertains to intellectual property in this area.
Source document (simplified)
ANTIGEN-BINDING PROTEINS TARGETING CD56 AND USES THEREOF
Publication EP3328994A1 Kind: A1 Mar 11, 2026
Applicants
Memorial Sloan-Kettering Cancer Center, The United States of America, as represented by
The Secretary, Department of Health and Human
Services
Inventors
SADELAIN, Michel, BENJAMIN, Reuben, DIMITROV, Dimiter, S., FENG, Yang
IPC Classifications
C12N 5/0783 20100101AFI20190313BHEP C07K 14/725 20060101ALI20190313BHEP C07K 16/30 20060101ALI20190313BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Peptides (C07K) publishes new changes.